AnaptysBio, Inc. (ANAB) — Analyst outlook / Analyst consensus target is. Based on 21 analyst ratings, the consensus is bullish — 15 Buy, 6 Hold.
The consensus price target is $73.71 (low: $50.00, high: $140.00), representing an upside of 5% from the current price $70.22.
Analysts estimate Earnings Per Share (EPS) of $-6.08 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-5.12 vs est $-6.08 (beat +15.9%). 2025: actual $-0.46 vs est $-1.45 (beat +68.2%). Analyst accuracy: 0%.
ANAB Stock — 12-Month Price Forecast
$73.71
▲ +4.97% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for AnaptysBio, Inc., the average price target is $73.71, with a high forecast of $140.00, and a low forecast of $50.00.
The average price target represents a +4.97% change from the last price of $70.22.
Highest Price Target
$140.00
Average Price Target
$73.71
Lowest Price Target
$50.00
ANAB Analyst Ratings
Buy
Based on 21 analysts giving stock ratings to AnaptysBio, Inc. in the past 3 months
EPS Estimates — ANAB
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$5.12
vs Est –$6.08
▲ 18.8% off
2025
Actual –$0.46
vs Est –$1.45
▲ 214.5% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ANAB
74%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.091B
vs Est $0.056B
▲ 38.7% off
2025
Actual $0.235B
vs Est $0.205B
▲ 12.5% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
